Clinical trial to assess potential treatment for COVID-19-related respiratory failure

April 06, 2020

Boston, Mass. - While the majority of people with COVID-19 won't require hospitalization, those who do are likely to seek medical help as a result of acute respiratory distress syndrome, or ARDS, a severe lung injury common in patients with critical illnesses. At present, there is no effective treatment for ARDS other than supportive care with mechanical ventilation.

A team of physician-scientists at Beth Israel Deaconess Medical Center (BIDMC) -- part of Beth Israel Lahey Health -- are now enrolling patients in a clinical trial to evaluate a common anti-clotting drug for the treatment of COVID-19-positive patients with ARDS. The newly launched trial follows a special report the team published in the Journal of Trauma and Acute Care Surgery that suggested the use of a drug called tPA could reduce deaths among patients with ARDS as a complication of COVID-19.

Epidemiological models predict that thousands of Americans will require mechanical ventilation in the coming months as a result of the COVID-19 pandemic, far exceeding the estimated 200,000 ventilators currently available in the United States.

"As the global pandemic of COVID-19 begins to oversaturate the world's medical capacity to accommodate a surge of patients with ARDS, it's critical we consider how existing therapies that are widely available may be of use in this unprecedented public health emergency," said the special report's lead author and clinical trial investigator, Christopher D. Barrett, MD, a senior surgical resident at BIDMC and a research fellow at MIT.

"If effective and safe for the treatment of ARDS in patients with COVID-19, tPA could save lives by reducing recovery time and freeing up more ventilators for other patients in need."

An anticoagulant naturally produced by the body, tPA was approved by the U.S. Food and Drug Administration in 1996 for use in patients experiencing heart attack, stroke and pulmonary embolism. Researchers have considered the use of anti-coagulant drugs to reduce ARDS-induced death for two decades. Though the approach has never been widely adopted or formally FDA-approved, a clinical observation made about a subset of patients with COVID-19 induced ARDS made the idea seem newly relevant.

"We're hearing anecdotally that a subset of patients with COVID-19 induced ARDS are clotting abnormally around their catheters and IV lines," said senior author, Michael B. Yaffe, MD, PhD, an attending surgeon in the departments of Acute Care Surgery, Trauma, and Surgical Critical Care, and in Surgical Oncology at BIDMC. "We suspect these patients with aggressive clotting are will show the most benefit from tPA treatment, and this new clinical trial will reveal whether that's the case."

Led by Yaffe, Barrett, and colleagues from BIDMC's Department of Anesthesia, Critical Care and Pain Medicine, including Shahzad Shaefi, MD, and Department Chair Daniel S. Talmor, MD, MPH, the tPA clinical trial is now open and enrolling patients with COVID-19 induced ARDS admitted to BIDMC. Next steps will include identifying biomarkers -- measurable characteristics such as blood levels of clotting factors -- to help more accurately determine which patients are most likely to respond to tPA as a treatment for ARDS, said Yaffe, who is also a Professor of Biology and Biological Engineering at the Massachusetts Institute of Technology.

The collaborative research was facilitated by Beth Israel Lahey Health COVID-19 Innovation Hub -- an effort led by Gyongyi Szabo, MD, PhD, Chief Academic Officer at Beth Israel Lahey Health -- to address the emerging challenges related to the pandemic.

Since the publication of the special report on March 23, Barrett and Yaffe have already heard from physicians across the country eager to try tPA for the treatment of COVID-19 induced ARDS. Because the medication is an FDA-approved drug already in widespread use for patients who have had heart attacks or strokes, doctors are permitted to prescribe it for off-label usage.
In addition to Barrett and Yaffe, co-authors on the special report included: Daniel S. Talmor, MD, Chief of the Division of Anesthesia, Critical Care and Pain Medicine at BIDMC; Hunter B. Moore MD, PhD, Ernest E. Moore MD, Peter K. Moore, MD, and Robert C. McIntyre MD, of the University of Colorado; Frederick A. Moore, MD, of the University of Florida, Gainesville.

About Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding. For more information, visit

BIDMC is part of Beth Israel Lahey Health, a new health care system that brings together academic medical centers and teaching hospitals, community and specialty hospitals, more than 4,000 physicians and 35,000 employees in a shared mission to expand access to great care and advance the science and practice of medicine through groundbreaking research and education.

Beth Israel Deaconess Medical Center

Related Trauma Articles from Brightsurf:

Early trauma influences metabolism across generations
A study by the Brain Research Institute at UZH reveals that early trauma leads to changes in blood metabolites - similarly in mice and humans.

Childhood trauma affects the timing of motherhood
Women who have experienced childhood trauma become mothers earlier than those with a more stable childhood environment shows a new study conducted in collaboration between the University of Turku and the University of Helsinki in Finland.

Trauma relapse in a novel context may be preventable
Korea Brain Research Institute (KBRI, President: Pann-Ghill Suh) announced on February 10 that its research team led by Dr.

Paving the way to healing complex trauma
A major study led by researchers at La Trobe University in Australia has identified key themes that will be used to inform strategies to support Aboriginal and Torres Strait Islander parents in the first years of their children's lives.

Improving trauma pain outcomes
A 7-year prospective cohort study from the Corporal Michael J.

Emotional trauma and fear most likely cause of 'Havana Syndrome'
The cause of the mystery illness among US and Canadian diplomats in Havana is most likely to be emotional trauma and fear according to a leading sociologist and an expert in neurodegenerative diseases, writing in the Journal of the Royal Society of Medicine.

Making a 'to do' list for trauma docs
Researchers from Drexel's College of Computing & Informatics have been integrating a tablet-based checklist tool into the workflow of a pediatric trauma center and, over the course of 15 months, have shown that it doesn't hamper doctors' performance.

Children develop PTSD when they 'overthink' their trauma
A new study shows that children are more likely to suffer PTSD if they think their reaction to a traumatic event is not 'normal'.

Disparities in access to trauma centers
An analysis of census tract data for neighborhoods in America's three largest cities suggests black-majority neighborhoods are associated with disparities in access to trauma centers.

Psychotic experiences could be caused by trauma in childhood
Researchers at the University of Bristol have made stronger links between psychotic experiences and different types of trauma in childhood.

Read More: Trauma News and Trauma Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to